Xencor, Inc. (XNCR)
| Previous close | 18.37 |
| Open | 18.39 |
| Bid | 18.35 x 100 |
| Ask | 18.54 x 200 |
| Day's range | 18.20 - 18.68 |
| 52-week range | 16.49 - 28.96 |
| Volume | |
| Avg. volume | 710,701 |
| Market cap | 1.119B |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.08 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 36.58 |
Business WireXencor Appoints Bart Cornelissen as Chief Financial Officer
PASADENA, Calif., April 09, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at
GuruFocus.comInsider Sell: SR. VICE PRESIDENT & CFO John Kuch Sells 4,474 Shares of Xencor Inc (XNCR)
John Kuch, Senior Vice President & Chief Financial Officer of Xencor Inc (NASDAQ:XNCR), has sold 4,474 shares of the company on March 5, 2024, according to a recent SEC filing.
GuruFocus.comInsider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)
Bassil Dahiyat, President & CEO of Xencor Inc (NASDAQ:XNCR), sold 12,528 shares of the company on March 5, 2024, according to a recent SEC Filing.
